(NASDAQ: ONCY) Oncolytics Biotech's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Oncolytics Biotech's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ONCY's revenue for 2027 to be $6,463,470,866, with the lowest ONCY revenue forecast at $6,463,470,866, and the highest ONCY revenue forecast at $6,463,470,866. On average, 1 Wall Street analysts forecast ONCY's revenue for 2028 to be $25,464,122,083, with the lowest ONCY revenue forecast at $25,464,122,083, and the highest ONCY revenue forecast at $25,464,122,083.
In 2029, ONCY is forecast to generate $42,460,656,581 in revenue, with the lowest revenue forecast at $42,460,656,581 and the highest revenue forecast at $42,460,656,581.